Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody–drug conjugates from synthetic antibody libraries

Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody–drug conjugates from synthetic antibody libraries

Abstract Mesothelin (MSLN) is an attractive candidate of targeted therapy for several cancers, and hence there are increasing needs to develop MSLN-targeting strategies for cancer therapeutics. Antibody–drug conjugates (ADCs) targeting MSLN have been demonstrated to be a viable strategy in treating...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hung-Ju Hsu, Chao-Ping Tung, Chung-Ming Yu, Chi-Yung Chen, Hong-Sen Chen, Yu-Chuan Huang, Pei-Hsun Tsai, Su-I Lin, Hung-Pin Peng, Yi-Kai Chiu, Yueh-Liang Tsou, Wei-Ying Kuo, Jhih-Wei Jian, Fei-Hung Hung, Chiao-Yun Hsieh, Michael Hsiao, Simon Shih-Hsien Chuang, Chia-Ning Shen, Yong Alison Wang, An-Suei Yang
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/1fd9e8c33c85491783497a53a3cfc809
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/1fd9e8c33c85491783497a53a3cfc809

Ejemplares similares